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Evidence increasingly shows that astrocytes play a pivotal role in brain physiology and pathology via
calcium dependent processes, thus the characterization of the calcium dynamics in astrocytes is of
growing importance. We have previously reported that the epidermal growth factor and basic ﬁbroblast
growth factor up-regulate the oscillation of the calcium releases that are induced by stimuli, including
glutamate in cultured astrocytes. This calcium oscillation is assumed to involve protein kinase C (PKC),
which is activated together with the calcium releases as a consequence of inositol phospholipid hy-
drolysis. In the present study, this issue has been investigated pharmacologically by using astrocytes
cultured with and without the growth factors. The pharmacological activation of PKC largely reduced the
glutamate-induced oscillatory and non-oscillatory calcium increases. Meanwhile, PKC inhibitors
increased the total amounts of both calcium increases without affecting the peak amplitudes and con-
verted the calcium oscillations to non-oscillatory sustained calcium increases by abolishing the falling
phases of the repetitive calcium increases. Furthermore, the pharmacological effects were consistent
between both glutamate- and histamine-induced calcium oscillations. These results suggest that PKC up-
regulates the removal of cytosolic calcium in astrocytes, and this up-regulation is essential for calcium
oscillation in astrocytes cultured with growth factors.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Evidence increasingly indicates that calcium dependent pro-
cesses in astrocytes play a pivotal role in brain physiology and pa-
thology. Intracellular calcium in astrocytes increases spontaneously
or in response to diverse stimuli, including neurotransmitters, hor-
mones, and lipid metabolites (1e3), and triggers the releases of
substances that affect neuronal activities or cerebral circulations
(4,5). Calcium increases also alter the structure and gene expression
of astrocytes (6). The spatiotemporal pattern of calcium increases in
astrocytes is altered by cytokine treatments in vitro and by patho-
logical conditions in vivo, including epilepsy and dementia (7e9),
suggesting that the calcium dynamics in astrocyte also participate in
pathological processes in the brain. Therefore, characterizing thee University Graduate School
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ons.org/licenses/by-nc-nd/4.0/).mechanismsunderlying the calcium increasepatternsof astrocytes is
an important issue for understanding brain functions and diseases.
We have previously demonstrated that epidermal growth factor
(EGF) and basic ﬁbroblast growth factor (bFGF) upregulate the
oscillation of the calcium releases that are induced by stimuli
including glutamate in astrocytes (7). In virtue of this ﬁnding, we
have established a deﬁned medium that is suitable to study the
astrocyte calcium oscillation, which is induced in a limited popu-
lation of the astrocytes cultured in a conventional serum-
containing culture media. Most of the astrocytes cultured in a
deﬁned medium containing growth factors release calcium in an
oscillatory manner, whereas the calcium release is largely non-
oscillatory if the astrocytes are cultured without the growth fac-
tors. This culture model has allowed us to demonstrate that the
astrocyte calcium oscillation is regulated by the mitogen-activated
protein kinase and the expression of sarco-endoplasmic reticulum
calcium ATPase (SERCA) (10).
In the present study, we have pharmacologically characterized
the involvement of protein kinase C (PKC) in the calcium dynamics
in astrocytes. PKC is activated by diacylglycerol and calcium, both of
which increase following receptor-induced inositol phospholipidr B.V. on behalf of Japanese Pharmacological Society. This is an open access article
Fig. 1. The effects of pharmacological modiﬁcations of PKC on glutamate-induced
calcium oscillations in astrocytes cultured with growth factors. (A) Representative
calcium increases. Cells were pretreated with 300 nM PMA or 10e1000 nM PKC in-
hibitors (Go6972, Go6983 or GFX) and then stimulated with 30 mM glutamate, as
indicated by the underlines. (B) Quantitative comparisons of calcium increases by
relative peak amplitude; DR(340/380)max and relative area under the graph; AUG.
Mean ± S.E.M. *p < 0.05, **p < 0.01, Tukey's multiple comparison method with control
(n ¼ 28 cells).
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by the activation of calcium-inducing metabotropic glutamate re-
ceptors, are mediated by PKC (11,12). Thus, PKC is likely to be active
during glutamate-induced calcium increases in astrocytes. A large
number of receptors and cellular machineries that are involved in
calcium dynamics have been reported as substrates of PKC (13).
Therefore, it is assumed that PKC inﬂuences the spatiotemporal
pattern of calcium increases in astrocytes. To reveal the contribu-
tion of PKC to the oscillatory and non-oscillatory patterns of cal-
cium increases in astrocytes, the present study has examined the
effects of pharmacological modiﬁcations of PKC on calcium in-
creases in astrocyte cultured in the presence or absence of growth
factors. Our results demonstrate that PKC is actively involved in
calcium dynamics in astrocytes.
2. Materials and methods
2.1. Cell culture
All of the animal experiments were approved by the Institu-
tional Animal Care and Use Committee of Tokyo University of
Pharmacy and Life Sciences or Kobe University (IACUC). Astrocytes
were isolated from the cerebral cortices of postnatal day 1 Wistar
rats, as described previously (14). Brieﬂy, brain cells were prepared
by trypsinization and cultured for 12 days in basal Eagle's medium
containing 10% fetal calf serum (FCS). The resulting mixed glial
culture was shaken at 260 rpm for 18 h to remove non-astrocytic
cells. The adherent cells were subcultured by trypsinization and
seeded in Dulbecco's Modiﬁed Eagle's medium (DMEM) containing
25 mM HEPES, pH 7.4, and 10% FCS. After 48 h, the medium was
changed to DMEM containing 25 mM HEPES, pH 7.4, 1 mM pyru-
vate, 2 mM glutamine, 50 mg/mL human apo-transferrin (Invi-
trogen, Carlsbad, CA), 10 ng/mL D-biotin, 5.2 ng/mL sodium
selenite, 1.5 mg/mL bovine ﬁbronectin (Invitrogen), 0.5 mg/mL
heparan sulfate, 5 mg/mL of insulin (Invitrogen), 10 ng/mL EGF
(Invitrogen), and 5 ng/mL bFGF (Invitrogen). The cells were
cultured for 48e96 h before the calcium imaging experiments,
whose results can be seen in Figs. 1 and 3. Astrocytes were cultured
without EGF and bFGF for the experiments that are illustrated in
Fig. 2.
2.2. Calcium imaging
The method that we used for the calcium imaging of the as-
trocytes in the deﬁned medium, included quantiﬁcation of calcium
ﬂuorescence values and setting region of interest, has been
described in detail in our previous paper (15). The cells were loaded
for 45 min at 30 C with 7.5 mM Fura2AM (Dojin, Kumamoto, Japan)
in basal salt solution (BSS), consisting of: 129 mM NaCl, 4 mM KCl,
1 mM MgCl2, 2 mM CaCl2, 4.2 mM glucose, and 10 mM HEPES
adjusted to pH 7.4 with NaOH. In all of the steps after loading,
100 mM sulﬁnpyrazone was added to the BSS. The durations of
pretreatment with phorbol 12-myristate 13- acetate (PMA),
Go6976, Go6983, and GF109203X (GFX) were 5 min, 60 min,
60 min, and 10 min, respectively. Calcium increases were induced
by adding agonists by perfusing at 1.5ml/min. Calcium imagingwas
performed using an IX70 inverted microscope, a UApo/340 40x/
1.15w objective, and an OSP-EXA ﬁlter exchanger (all from
Olympus, Tokyo, Japan) equipped with a C6790 CCD camera
(Hamamatsu Photonics, Hamamatsu, Japan). Fluorescence images
were acquired and the R340/380 ratios were calculated using
AQUACOSMOS software (Hamamatsu Photonics). Each quantitative
analysis of a calcium increase represents at least four imaging ex-
periments using two series of cultures from two different cell
preparations.2.3. Chemicals
Go6976 and Go6983 were from Calbiochem (Cambridge, MA,
USA). GF109203X (GFX) was obtained from Enzo Life Sciences
(Farmingdale, NY, USA). Unless otherwise indicated, the chemicals
were supplied by Sigma (St. Louis, MO, USA).
3. Results
3.1. Glutamate-induced calcium oscillation
The involvement of PKC in the glutamate-induced calcium os-
cillations in astrocytes cultured with growth factors has been
investigated pharmacologically. As shown in Fig. 1, the PKC
Fig. 2. The effects of pharmacological modiﬁcations of PKC on the glutamate-induced
sustained calcium increases in astrocytes cultured without growth factors. (A)
Representative calcium increases. Cells were pretreated with 300 nM PMA or 1 mM PKC
inhibitors (Go6972, Go6983 or GFX) and then stimulated with 30 mM glutamate, as
indicated by underlines. (B) Quantitative comparisons of calcium increases by relative
peak amplitude; DR(340/380)max and relative area under the graph; AUG.
Mean ± S.E.M. **p < 0.01, Tukey's multiple comparison method with control
(n ¼ 28 cells).
Fig. 3. The effects of pharmacological modiﬁcations of PKC on the histamine-induced
calcium oscillations in astrocytes cultured with growth factors. (A) Representative
calcium increases. Cells were pretreated with 300 nM PMA or 1 mM PKC inhibitors
(Go6972, Go6983 or GFX) and then stimulated with 30 mM histamine, as indicated by
underlines. (B) Quantitative comparisons of calcium increases by relative peak
amplitude; DR(340/380)max and relative area under the graph; AUG. Mean ± S.E.M.
**p < 0.01, Tukey's multiple comparison method with control (n ¼ 28 cells).
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tudes and the area under the graphs (AUG), representing the in-
tegral of the calcium increases by 62% and 76%, respectively. A
selective inhibitor of calcium dependent PKC isoforms (cPKC),
Go6976, was used at 10, 100, and 1000 nM, and signiﬁcantly
increased the AUG by 20%, 27% and 39%, respectively, without
affecting the peak amplitudes. Broad-spectrum PKC inhibitors,
Go6983 and GFX, increased the AUG by 47% and 65%, respectively,
without affecting the peak amplitudes at 1000 nM but not affecting
them at 10 and 100 nM. These results indicate that PKC is activated
during the glutamate stimulations and suppresses the calcium in-
creases, especially in the falling phases during the repetitive cal-
cium increases.3.2. Glutamate-induced non-oscillatory calcium increase
The involvement of PKC in non-oscillatory calcium increases in
astrocytes cultured without growth factors was examined phar-
macologically. As shown in Fig. 2, PMA signiﬁcantly reduced both
the peak amplitudes and the AUG of the calcium increases by 80%
and 79%, respectively. 1 mM Go6976 did not affect the calcium in-
crease, whereas Go6983 and GFX at the same concentration
signiﬁcantly increased the AUG by 39% and 37%, respectively,
without affecting the peak amplitudes. These results indicate that
PKC suppressed the glutamate-induced non-oscillatory calcium
increases in a similar manner to the oscillatory calcium increases,
but not involving cPKC.3.3. Histamine-induced calcium oscillation
To address the stimulation speciﬁcity of the involvement of PKC
in the calcium oscillation, the histamine-induced calciumoscillations in the astrocytes cultured with the growth factor have
been examined pharmacologically. As shown in Fig. 3, PMA
signiﬁcantly reduced both the peak amplitudes and the AUG of the
calcium increases by 28% and 40%, respectively. Go6976, Go6983,
and GFX increased the AUG by 30, 37, and 32%, respectively,
without affecting peak amplitudes. These results indicate that PKC
is similarly involved in the histamine-induced calcium oscillations
in astrocytes.4. Discussion
To address the involvement of PKC in the calcium dynamics in
astrocytes, the present study examined the effects of the pharma-
cological modiﬁcations of PKC on glutamate- or histamine-induced
calcium releases in astrocytes cultured in conditions preferentially
up-regulate or down-regulate of the calcium oscillations. The PKC
activation by PMA largely reduced the peak amplitudes and the
AUG of both oscillatory and non-oscillatory calcium releases.
Furthermore, the effect of PMA was consistent between the gluta-
mate- and histamine-induced calcium oscillations. Thus, the acti-
vation of PKC presumably leads to the suppression of the cellular
machineries involved in the calcium releases. PKC phosphorylates
phospholipase Cb (PLCb) and reduces the inositol phospholipid
hydrolysis via G protein signaling by blocking the coupling between
PLCb and G protein (16,17). PKC also phosphorylates the type 2
inositol 1,4,5 trisphosphate (IP3) receptor, which is the dominant
subtype in astrocytes, and reduces the afﬁnity to IP3 (18,19).
Furthermore, PKC phosphorylates and desensitizes mGluR5, which
Fig. 4. PKC in astrocyte calcium dynamics. The left half represents the glutamate-
induced calcium oscillation in astrocytes cultured in the presence of growth factors,
whereas the right half represents the glutamate-induced non-oscillatory calcium in-
creases in an astrocyte cultured without growth factors. The growth factors (GF) (1)
up-regulates astrocyte calcium oscillation by increasing SERCA2B expression (2) and
calcium store size. Glutamate stimulation (3) induces IP3 production via mGluR5 (4).
IP3 induces calcium release from Type 2 IP3 receptor (IP3R2) and the calcium is
reabsorbed by SERCA2B (5). mGluR5 also increases diacylglycerol production, which
activates PKC (6). In the GF-treated astrocytes, intracellular calcium is also involved in
PKC activation (7). PKC enhances SERCA-mediated removal of cytosolic calcium (8). The
PKC activator, PMA, up-regulates the process represented by (8). The broad-spectrum
PKC inhibitors, Go6983 and GFX, block the process represented by (8), whereas the
cPKC inhibitor, Go6976, blocks the PKC isoforms activated synergistically by the pro-
cesses represented by (6) and (7).
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the histamine H1 receptor (20,21). Since each of these suppressions
is less than a 50% reduction, the robust inhibitory effect of PMA is
assumed to reﬂect the synergistic inﬂuence of these inhibitions.
In our previous studies we have quantiﬁed the number of peaks
during calcium increases and determined the inﬂuence of growth
factors and cytokines, or agonist concentrations, on calcium oscil-
lations (7,15). Although the same quantiﬁcation method was used
in the present study to determine the concentration-dependent
effects of PKC inhibitors on the calcium oscillation in astrocytes,
clear results were not obtained. The PKC inhibitors did not simply
reduce the number of peaks, they also increased the variance. The
conditions that we used to detect the peaks signiﬁcantly affected
the results of our quantiﬁcation. Thus, the present study quantiﬁed
the pharmacological effects by measuring the peak amplitude and
the AUG of the calcium increases, and interpreted the results by
focusing on the removal of cytosolic calcium.
The broad-spectrum PKC inhibitors, Go6983 and GFX increased
the AUG of oscillatory and non-oscillatory calcium increases
without affecting the peak amplitudes. The calcium oscillations
were converted to non-oscillatory sustained calcium increases, due
to the increase of calcium concentration between peaks. Thus, two
inhibitors most likely abolished the falling phase of the repetitive
calcium increases by inhibiting the removal of cytosolic calcium. It
has been demonstrated that the excretion of cytosolic calcium by
plasma membrane calcium ATPase is activated by PKC following
inositol phospholipid hydrolysis, and plays a crucial role in
reducing cytosolic calcium to the basal level in neurons (22). Naþ/
Ca2þ exchanger 1, which is a dominant subtype in astrocytes, is also
activated by PKC (23,24). Our previous study has demonstrated that
the calcium oscillations of astrocytes cultured in a deﬁned medium
containing the growth factors persist even in the absence of
extracellular calcium (7). Consequently, a large portion of the
cytosolic calcium is likely to be absorbed into the endoplasmic re-
ticulum by SERCA to maintain the repeated calcium releases in the
astrocytes. Thus, it is suggested that the PKC inhibitors increases
the AUG of the oscillatory and non-oscillatory calcium releases by
inhibiting the PKC-mediated SERCA activation. Although PKC has
been shown to up-regulate the SERCA-mediated calcium absorp-
tion in neurons, it is still to be determined if PKC activates SERCA by
direct phosphorylation or by phosphorylating proteins regulating
SERCA (25). As shown in our previous study, the increase of the
SERCA expression underlies the up-regulation of the astrocyte
calcium oscillation by the growth factors (10), thus it is suggested
that the SERCA activity is maintained to an extent that is sufﬁcient
for the calcium oscillations, not only by gene expression but also by
the PKC-mediated activation following inositol phospholipid hy-
drolysis. The present results do not exclude the possibility that the
PKC inhibitors suppress the phosphorylation of the receptors and
calcium release machineries, which are also targets of PKC, as
mentioned above, and increase the AUG. However, if this is the case,
then the peak amplitudes are more likely to be affected.
The cPKC selective inhibitor, Go6976, increased the AUG of the
glutamate-induced calcium oscillations, even at 10 nM, which is
100 times lower than the effective concentration of broad PKC in-
hibitors, whereas it did not affect the non-oscillatory calcium in-
creases. The selective effect of Go6976 on calcium oscillations
suggests that cPKC is more effectively activated during calcium
oscillation in astrocytes, as previously reported in other cell types
(26). The up-regulation of cPKC isoforms in astrocytes by the
growth factors may underlie the selective effect of Go6976. The
effect of Go6976 at lower concentrations may reﬂect the involve-
ment of PKCm, which Go6976 inhibits more potently than Go6893
and GFX (27). It has been reported that PKCm, which is also desig-
nated as PKD, is activated during receptor stimulation; leading toinositol phospholipid hydrolysis in astrocytes (28). Further analysis
on the expressions of PKC isoforms in astrocytes, with or without
growth factor treatments, will address the unique effects of
Go6976.
The calcium increases were suppressed by PMA but enhanced
by broad-spectrum PKC inhibitors. This suggests that the receptor
stimulations to induce inositol phospholipid hydrolysis and cal-
cium releases activates PKC to an extent which is smaller than the
activation by PMA. The present result suggests that this interme-
diate activation of PKC inﬂuences both oscillatory and non-
oscillatory calcium increases in the same manner. Thus, it is
considered that the growth factors are less likely to regulate cal-
cium oscillation by altering PKC pathways. However, it is still
possible to assume that the growth factors alter the expression of
PKC isoforms, especially cPKC, and modify the PKC pathways for
generating the calcium oscillation. If the growth factors make the
intermediate activation of PKC more calcium dependent by
increasing the expression of cPKC, then the calcium absorption by
SERCA, which is likely to be enhanced by PKC (as discussed above),
will also become more calcium dependent and will preferentially
contribute to calcium oscillation. The assumed contribution of the
intermediate activation of PKC to astrocyte calcium dynamics are
summarized in Fig. 4. The growth factors increases SERCA on cal-
cium store and enlarge store size (1,2). Glutamate stimulation (3)
induces calcium release from IP3R2 (4,5) and partially activates
M. Morita et al. / Journal of Pharmacological Sciences 129 (2015) 38e4242PKC (6). In growth factor treated cells, calcium release enhances
PKC activation (7), which positively regulates the calcium uptake by
SERCA2B (8). Calcium oscillation in growth factor treated astrocytes
is likely attributed to the synergistic effect of the calcium depen-
dent SERCA activation via PKC and increased capacity of the calcium
uptake. Further analysis of the expression of PKC isoforms and
isoform selective ablation by siRNA or genome editing will address
this issue. The present pharmacological data demonstrate that the
calcium dynamics in astrocytes are under the inﬂuence of PKC and
that PKC is an effectivemeans to control the spatiotemporal pattern
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